MARLBOROUGH, Mass. — Sunovion Pharmaceuticals Inc. has released Seebri Neohaler Inhalation Powder (glycopyrrolate 15.6 mcg), a treatment for chronic obstructive pulmonary disease (COPD), to U.S. pharmacies. Sunovion said Thursday that it entered into an exclusive license agreement with Novartis for the U.S. commercialization rights to Seebri Neohaler, as well as Utibron Neohaler and Arcapta Neohaler, in
LONDON and OSAKA, Japan — AstraZeneca plans to acquire the core respiratory business of Takeda Pharmaceutical Co. Ltd. for $575 million. Under the agreement, approximately 200 Takeda staff will transfer to AstraZeneca after the closing of the transaction, expected in the first quarter of 2016. AstraZeneca said the deal will include the expansion of rights
RIDGEFIELD, Conn. — Boehringer Ingelheim has received approval from the Food and Drug Administration for Stiolto Respimat Inhalation Spray, a medication for chronic obstructive pulmonary disease (COPD). The company said Tuesday that Stiolto Respimat Inhalation Spray (tiotropium bromide and olodaterol) was approved as a long-term, once-daily maintenance treatment for airflow obstruction in patients with COPD,
